Therefore, the oral calcitriol therapy-induced changes in oxidized albumin ratio or improves the oxidative status in HD patients by a mechanism other than the reduction in indoxyl sulfate or elevation in SOD activity. The gene discussed is SOD1; the disease is Huntington disease.